Scioto Biosciences

Live Bacterial Therapeutics Indiana, USA

| Overview |

Scioto Biosciences has developed a Phase II-ready drug candidate which has demonstrated clinically meaningful results in patients with autism spectrum disorder.

Our Services

Sector

Therapeutics

Round

Series C

Transaction

Capital Raise

Transaction Value

Undisclosed

Space

Activated Bacterial Therapeutics

Milestones

Founded 2017
Completed Phase I by 2022

Investors

Elevate Ventures

Indiana University Philanthropic Fund

Rev1 Ventures

Founders

Joe Trebley, PhD Jim Schulz, CPA

Webste

sciotobiosciences.com

Challenge

Lack of standard of care treatments.

While the CDC estimates that greater than 2% of all children have autism spectrum disorder, and that it’s prevalence is growing at 7% a year, no current standard of care treatments exist.

Solution

ABT: Revolutionizing Therapeutic Interventions

An Activated Bacterial Therapeutic platform which allows for delivery of microbiome-targeting bacteria, allowing for direct modulation of autism and other nervous system disease pathways.

Impact